Nvidia Corp (NASDAQ:NVDA) announced a partnership with Aidoc, a startup that provides healthcare organizations with artificial intelligence (AI) tools to improve workflow, data accuracy, and overall patient care.
The companies will work on a new framework, “Blueprint for Resilient Integration and Deployment for Guided Excellence” (BRIDGE), aimed at accelerating AI adoption across the healthcare industry.
Also read: Microsoft launches healthcare AI tools to help analyze biomedical data
Scheduled for release in early 2025, the guidelines will introduce a comprehensive, evidence-based framework to more effectively integrate AI into clinical workflows.
We aim to help healthcare organizations accelerate AI innovation with confidence. This guideline outlines strategies for health systems to maximize the potential of AI to improve patient outcomes.
Although more than 900 FDA-cleared AI tools for medical imaging have been approved, healthcare systems continue to face fragmentation, operational inefficiencies, and scalability challenges.
The BRIDGE Guidelines provide a comprehensive, vendor-neutral roadmap to address these issues, enabling providers to maximize the benefits of AI.
“AI has the potential to revolutionize patient care, but progress is slowed by fragmented systems that cannot scale effectively,” said Demetri Giannikopoulos, Chief Transformation Officer at Aidoc. states. “The BRIDGE guidelines focus on breaking down these barriers and provide a strong evidence-based framework to help health systems not only adopt AI, but extend it across their operations. This increases operational efficiency and significantly improves outcomes for both patients and clinicians.”
The BRIDGE guidelines aim to establish a foundation aligned with industry frameworks like MONAI to serve as a blueprint for a healthcare AI enterprise platform.
MONAI was co-founded in 2019 by academic and industry leaders, including NVIDIA, to provide essential tools for the development, validation, and deployment of medical AI.
With over 3 million downloads and actively used in FDA-approved medical device software applications, MONAI's focus on standardization, interoperability, and scalability drives innovative medical solutions. It is important to
Price Action: NVDA stock was up 0.32% at $138.32 at last check on Monday.
Read next:
Photo by PopTika on Shutterstock
Next step: Transform your trading with Benzinga Edge's unique market trading ideas and tools. Click now to access exclusive insights that can give you an edge in today's competitive market.
story continues
Want the latest stock analysis from Benzinga?
This article Nvidia partners with startup Aidoc to accelerate healthcare AI adoption.
© 2024 Benzinga.com. Benzinga does not provide investment advice. Unauthorized reproduction is prohibited.
